A series of dementia relieving drugs will not be available to Alzheimer's sufferers following a ruling by the National Institute of Health and Clinical Excellence (NICE).
The drugs still got a step up from their previous "not useful" ruling, now maintaining the set of medications are only useful in the moderate stages of Alzheimers.
NICE chief executive Andrew Dillon was apologetic to the stakeholders that want the drug available for all patients of the disease.
"We have to be honest and say that based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough of a difference for us to recommend their use for treating all stages," he said.
The drugs donepezil, galantamine and rivastigmine will only be available through the NHS for new sufferers once they are considered to be in the disease's moderate stage but all current drug users will be able to continue their treatment.